655 related articles for article (PubMed ID: 32772795)
1. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
Cosimati A; Rossi L; Didona D; Forcella C; Didona B
J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
[TBL] [Abstract][Full Text] [Related]
2. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.
Lopez AT; Geskin L
Oncologist; 2018 Oct; 23(10):1119-1126. PubMed ID: 30018132
[TBL] [Abstract][Full Text] [Related]
3. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
Parakh S; Nguyen R; Opie JM; Andrews MC
Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
[TBL] [Abstract][Full Text] [Related]
4. Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab.
Adachi E; Honda T; Nonoyama S; Irie H; Yamamura K; Otsuka A; Kabashima K
J Dermatol; 2019 Jul; 46(7):e232-e233. PubMed ID: 30758879
[No Abstract] [Full Text] [Related]
5. Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report.
Muto Y; Namikawa K; Fujiwara Y; Mori T; Nakano E; Takahashi A; Yamazaki N
J Dermatol; 2020 Jan; 47(1):e9-e11. PubMed ID: 31674068
[No Abstract] [Full Text] [Related]
6. [Bullous pemphigoid induced by cancer immunotherapy].
Giroud S; Chiticariu-Durr E
Rev Med Suisse; 2020 Apr; 16(688):624-628. PubMed ID: 32239835
[TBL] [Abstract][Full Text] [Related]
7. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy.
Guan S; Zhang L; Zhang J; Song W; Zhong D
Front Immunol; 2022; 13():1068978. PubMed ID: 36685586
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer.
Schwartzman G; Simpson MM; Jones R; Schiavone K; Coffman M; Meyerle J
Cutis; 2020 Jun; 105(6):E9-E12. PubMed ID: 32716997
[TBL] [Abstract][Full Text] [Related]
9. Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid.
Zhang X; Sui D; Wang D; Zhang L; Wang R
Front Immunol; 2021; 12():731774. PubMed ID: 34594337
[TBL] [Abstract][Full Text] [Related]
10. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
11. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
Wada N; Uchi H; Furue M
J Dermatol; 2017 Oct; 44(10):e240-e241. PubMed ID: 28677843
[No Abstract] [Full Text] [Related]
12. A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication.
Bezinelli LM; Eduardo FP; Migliorati CA; Ferreira MH; Taranto P; Sales DB; Santi CG; Macarenco RS; Godoy CPV; Corrêa L; Buzaid AC
J Immunother; 2019; 42(9):359-362. PubMed ID: 31246641
[TBL] [Abstract][Full Text] [Related]
13. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.
Carlos G; Anforth R; Chou S; Clements A; Fernandez-Peñas P
Melanoma Res; 2015 Jun; 25(3):265-8. PubMed ID: 25831416
[TBL] [Abstract][Full Text] [Related]
14. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report.
Pop SR; Strock D; Smith RJ
Dermatol Ther; 2022 Aug; 35(8):e15623. PubMed ID: 35669992
[No Abstract] [Full Text] [Related]
16. Pembrolizumab-induced reactivation of bullous pemphigoid.
Kaul S; Wang A; Grushchak S; Albrecht J
Int J Dermatol; 2021 Jun; 60(6):757-758. PubMed ID: 33615441
[No Abstract] [Full Text] [Related]
17. Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma.
Ványai B; Chien YC; Beke L; Szabó IL; Péter Z; Steuer-Hajdu K; Várvölgyi T; Méhes G; Emri G
Immunotherapy; 2022 Dec; 14(17):1377-1382. PubMed ID: 36475303
[TBL] [Abstract][Full Text] [Related]
18. Development of Thyroid Carcinoma During Treatment With Pembrolizumab in a Lung Cancer Patient.
Gorospe L; García-Gómez-Muriel I; Pian-Arias HG; Gómez-Ramírez J; Rioja-Martín ME; Olmedo-García ME; Garrido-López P; Muñoz-Molina GM; Mezquita L
Ann Thorac Surg; 2020 Jun; 109(6):e397-e399. PubMed ID: 31846639
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab-induced lichen planus pemphigoides in a patient with metastatic non-small-cell lung cancer.
Senoo H; Kawakami Y; Yokoyama E; Yamasaki O; Morizane S
J Dermatol; 2020 Apr; 47(4):e121-e122. PubMed ID: 31984550
[No Abstract] [Full Text] [Related]
20. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
